IDRI Signs Lease with Alexandria Real Estate Equities, Inc. for New Seattle Headquarters

May 30th, 2012|Press Releases|

Seattle, WA | May 30, 2012 The Infectious Disease Research Institute (IDRI) has officially signed a new lease in Seattle’s South Lake Union neighborhood with long-time real estate partner Alexandria Real Estate Equities, Inc.  IDRI intends to relocate in [...]

AERAS and IDRI Sign Agreement to Jointly Develop Novel Tuberculosis Vaccine

May 9th, 2012|Press Releases|

Rockville, MD | Seattle, WA | May 9, 2012 Aeras and the Infectious Disease Research Institute (IDRI) announce today a new agreement to conduct joint development activities with respect to IDRI’s novel tuberculosis vaccine candidate. This collaboration reflects the [...]

IDRI Quest for Leprosy Vaccine Closer to Reality with Help of Million Dollar Grant

March 8th, 2012|Press Releases|

Seattle, WA | March 8, 2012 Leprosy, otherwise referred to as Hansen's Disease, is one of the most ancient diseases known to humans. Although the World Health Organization declared leprosy to be under control in many previously endemic countries, [...]

First Vaccine Against Fatal Visceral Leishmaniasis Enters Clinical Trial

February 22nd, 2012|Press Releases|

Seattle, WA | February 22, 2012 The first clinical trial of a new vaccine for visceral leishmaniasis (VL) has been launched by the Infectious Disease Research Institute (IDRI), a Seattle-based nonprofit that develops products to prevent, detect, and treat [...]

IDRI Supports the First Phase 1 Human Hookworm Vaccine Clinical Trial

January 31st, 2012|Press Releases|

Seattle, WA | January 31, 2012 The Infectious Disease Research Institute (IDRI) announced its technical support of the Sabin Vaccine Institute's (Sabin) first ever Phase 1 clinical trial of a human hookworm vaccine candidate, which began last week in [...]

IDRI Awarded Additional Funds for Novel TB Drugs

January 11th, 2012|Press Releases|

Seattle, WA | January 11, 2012 The Infectious Disease Research Institute (IDRI) announced today the receipt of supplemental funds from the Bill & Melinda Gates Foundation, totaling over half a million dollars to augment the multi-million dollar award made [...]

Human trials initiated for new HIV vaccine

December 21st, 2011|Press Releases|

Seattle, WA | December 21, 2011 In the first clinical trial of an injectable vaccine containing trimeric HIV envelope protein (gp140) relevant to the predominant strain of HIV in Africa, researchers from four UK academic centers (St George's University [...]

IDRI Announces New VP Tuberculosis Drug Development: Gail H. Cassell, PhD, to Join IDRI

December 7th, 2011|Press Releases|

Seattle, WA | December 7, 2011 The Infectious Disease Research Institute (IDRI) announced today that Dr. Gail H. Cassell has joined IDRI as its Vice President, TB Drug Development. In this newly created position, Dr. Cassell will work within [...]

IDRI to Present at India — US Forum: Dr. Christopher Fox to Discuss IDRI’s Technology Transfer Efforts

November 29th, 2011|Press Releases|

Seattle, WA | November 29, 2011 The Infectious Disease Research Institute (IDRI) announced today that IDRI formulation scientist Dr. Christopher Fox will present at this week's Forum on The US-India Commercial Relationship: The Knowledge Economy. The forum, to be [...]

Eli Lilly and Company Provides IDRI with Additional Funding for Identification of New Tuberculosis Therapies

November 17th, 2011|Press Releases|

Seattle, WA | November 17, 2011 The Infectious Disease Research Institute (IDRI) has been awarded more than $4 million in additional funding over the next four and a half years by Eli Lilly and Company. The funding will support [...]

Load More